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Lung cancer is the primary cause of cancer mortality in developed countries. First diagnosis only when disease has already reached the
metastatic phase is the main reason for failure in treatment. To this regard, although low-dose spiral computed tomography (CT) has
proven to be effective in the early detection of lung cancer (providing both higher resectability and higher long-term survival rates),
the capacity of annual CT screening to reduce lung cancer mortality in heavy smokers has yet to be demonstrated. Numerous
ongoing large-scale randomised trials are under way in high-risk individuals with different study designs. The initial results should be
available within the next 2 years.
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THE MAGNITUDE OF THE PROBLEM
Lung cancer kills more than 1.3 million people every year (Peto
et al, 1996), with figures registering a continual increase in the Far
East in countries such as China (Yang et al, 2004). Improvements
in clinical management have been modest over the past 20 years,
with an overall 5-year survival rate just above 10% in Europe
(Verdecchia et al, 2007). Presence of metastatic disease at
diagnosis is the main reason for treatment failure, and 5-year
survival of patients resected in stage Ia is 470% (Goldstraw et al,
2007). In developed countries, smoking sanctions have achieved a
significant reduction in the prevalence of active smokers and lung
cancer mortality in males, but not yet in females (Levi et al, 2003).
Despite the success of early prevention, a large cohort of former
smokers remain at high risk of cancer for many years.
PREVIOUS RESEARCH INVOLVING OTHER
MODALITIES
Early detection trials with chest radiography (CXR) and sputum
cytology, funded by the US National Cancer Institute in the 1970s,
were ineffective in decreasing lung cancer mortality, despite the
higher proportion of early-stage cancer identified through screen-
ing (Melamed et al, 1984). Quite unexpectedly, the 25-year follow-
up of the Mayo trial showed that overall mortality was higher in
the CXR arm compared with the standard care arm (difference not
reaching statistical significance, P¼0.09), even though the survival
rate of lung cancer patients diagnosed at an early stage in the CXR
arm was much higher (69 vs 54% at 5 years, median 16 years vs 5
years, respectively) (Marcus et al, 2006). These results confirmed
the inefficacy of CXR monitoring, as well as the occurrence of
overdiagnosis in the intervention arm.
OBSERVATIONAL STUDIES WITH LOW-DOSE
SPIRAL CT
The advent of low-dose spiral chest computed tomography (LDCT)
opened a new perspective for early diagnosis, and initial
studies conducted in Japan in the 1990s demonstrated the potential
value of LDCT for lung cancer screening (Kaneko et al, 1996).
Since then, the rapid technological development in multislice
machines has improved the sensitivity and reliability of spiral CT,
providing the concrete possibility of detecting pulmonary lesions
of 3–4mm in size in a few seconds, without the use of intravenous
contrast.
In 1999, the Cornell University of New York published the first
results of the Early Lung Cancer Action Project (ELCAP), showing
that spiral CT scans had accuracy and sensitivity rates that were six
times higher than CXR results in identifying very small lung
tumours (56% o1cm) with a resectability rate of 96% and a
frequency of stage I neoplasms of 85%. This study provided solid
guidelines for the management of CT-detected pulmonary lesions,
including needle aspiration biopsy of small pulmonary lesions
(Henschke et al, 1999).
The results of observational studies, including 64475 subjects,
are summarised with relative references in Table 1. The median age
was 59 years (range 53–67), with minimum age ranging from 40 to
60 years. Five studies included non-smokers, representing 17–54%
of participants in each trial, and an overall proportion of 20%. In
the remaining eight studies, the median pack-years (p-y) was 43
years (range 30–45).
At baseline, the overall frequency of participants with suspicious
non-calcified solid lesions was 20% (range 7–53), lung cancer
detection rate was 1% (range 0.4–2.7), and the proportion of stage
I lung cancer was 81% (range 50–100%). The two extensive
Japanese studies (Sone et al, 2001; Nawa et al, 2002) that included a
significant proportion of non-smokers (38–54%) had the lowest
frequency of baseline lesions (7–11%) and lung cancer detection
rates (0.4–0.5%). On the other hand, the highest baseline detection
rate (2.7%) reported by Henschke et al (1999) is mainly
attributable to the accrual of heavier smokers above the age of
60 years (median 67years, 45p-y) and prolonged diagnostic
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www.bjcancer.comworkup of lesions detected at baseline (up to 2 years). In fact, in
the more recent Korean study (Chong et al, 2005), in which nearly
half of the 6406 participants were low risk and 23% were non-
smokers, the lung cancer detection rate at baseline was only 0.4%.
Interestingly, the use of the latest generation spiral CTs (8–16
slice) increased the frequency of subjects with suspicious nodules
above 50%, but the lung cancer detection rate was not substantially
greater (1.1%) (Veronesi et al, 2008). Ten studies reported the
number of lung cancers detected at first annual CT repeat
(Table 1): a total of 197 cases from 56252 subjects, corresponding
to a 0.3% rate (range 0.1–1.4) and a cumulative frequency at 2
years of 1.4% (range 0.6–2.6).
In studies in which the enrolled population demonstrated
similar cancer risk factors, most of the differences observed in the
baseline detection rate were related to the diagnostic algorithm, the
analysis of CT images, and the definition of a positive screen
applied by each centre, and tended to level up with the first CT
repeat. In fact, excluding the two Japanese studies with a high
proportion of non-smokers, the cumulative lung cancer detection
rate by the second year of screening was 1.6% (range 1.3–2.6,
Table 1).
RANDOMISED TRIALS WITH LOW-DOSE SPIRAL CT
A number of randomised trials are currently being performed
worldwide, involving more than 90000 individuals (Table 2).
Of particular interest is the Lung Screening Study (LSS), a
completed feasibility trial carried out in the United States, which
randomised 3318 smokers (age 55–74 years, X30p-y, median
54p-y) to LDCT or CXR, performed at baseline and first year
repeat (Gohagan et al, 2005). The LSS confirmed LDCT’s higher
lung cancer detection rate compared with CXR: 1.8 vs 0.5% at
baseline, and 2.4 vs 1.3% at the first year repeat. On the basis of the
success of LSS, the National Cancer Institute, in collaboration with
the American College of Radiology Imaging Network, launched the
National Lung Screening Trial, which represents the largest
randomised controlled trial comparing LDCT with CXR, with lung
cancer mortality as the end point (Clark et al, 2008). More than
53000 participants were enrolled from over 30 centres across the
United States. The National Lung Screening Trial has 90%
statistical power to detect a 20% reduction in lung cancer
mortality in the LDCT arm. The trial design included three
annual screening examinations, which were completed in 2006,
and subjects are currently in follow-up, with final results expected
in 2011.
The European screening programme currently includes six
randomised studies: the NELSON trial in the Netherlands, the
Danish Lung Cancer Screening Trial in Denmark, The LUSI trial in
Germany, and three Italian studies, namely, DANTE-Milan and
ITALUNG-Florence, and MILD-Milan, all comparing annual CTs
with observation without screening.
The NELSON trial was designed to detect a 25% reduction in
lung cancer mortality in subjects aged 50–74 years having smoked
415 cigarettes per day for 425 years, or 410 cigarettes per day
for 430 years, with a planned population of 20000 subjects and
three 16-slice CT examinations at years 1, 2, and 4 in the screening
arm (van den Bergh et al, 2008). The NELSON trial accrued nearly
16000 individuals in the Netherlands and Belgium, and the
remaining 4000 needed to reach statistical power were recruited
from Denmark. Initial results of Nelson have shown a 0.9% lung
cancer detection rate at baseline, with a 99.9% negative predictive
value of the diagnostic algorithm, based on the automated
assessment of volume and doubling time (van Klaveren et al,
2009). The proportion of invasive procedures that revealed benign
disease was 27.2%. The Danish Lung Cancer Screening Trial has a
similar risk population (50–70years, X20p-y), but includes
annual CT screening for 5 years, with results regularly uploaded
into the Nelson database. The baseline lung cancer detection rate
of the Danish Lung Cancer Screening Trial was similar to the one
of Nelson (0.8%) (Pedersen et al, 2009).
A similar trial, LUSI, was launched in Germany in 2007, and is
now in the randomisation phase (Becker et al, 2008).
The DANTE-Milan study was the first European randomised
trial to be launched in 2001, enrolling 2472 subjects (60–74years,
X20p-y) in annual CT screenings or in observation for 4 years
(Infante et al, 2008). At baseline, participants in both arms had to
undergo one single CXR and sputum cytology examination, which
led to lung cancer detection in eight patients in the control arm.
The ITALUNG-Florence randomised 3206 subjects (55–69years,
X20p-y) to annual CT vs observation for 4 years. Baseline CT
detected 21 lung cancers in 20 subjects (1.5%) (Lopes Pegna et al,
2009). The Multicentric Italian Lung Detection trial started in
Milan in 2005 and is still open to accrual. Until now, more than
4400 participants have been assigned to LDCT or control, for a
period of 10 years. In the LDCT arm, a second randomisation has
been planned to compare yearly CT screening with testing every 2
years. All participants will undergo an antitobacco counselling
Table 1 Lung cancer CT screening: results of observational studies
Lung cancers
Subjects Age (years)
a NSM
b p-y
c CT lesions
d Baseline
e Stage I
f First repeat
g
Henschke et al, 1999 1000 67 0 45 233 (23) 27 (2.7) 85 —
Sone et al, 2001 5483 64 54 — 588 (11) 23 (0.4) 100 27 (0.5)
Nawa et al, 2002 7956 56 38 — 541 (7) 36 (0.5) 78 4 (0.1)
Sobue et al, 2002 1611 59 14 — 186 (12) 14 (0.9) 71 22 (1.4)
Diederich et al, 2004 817 53 0 45 350 (43) 12 (1.5) 64 —
Swensen et al, 2003 1520 59 0 45 780 (51) 27 (1.7) 74 13 (0.9)
Pastorino et al, 2003 1035 58 0 40 199 (19) 11 (1.1) 55 11 (1.1)
Bastarrika et al, 2005 911 55 0 30 291 (32) 12 (1.3) 83 2 (0.2)
Chong et al, 2005 6406 55 23 — 2,255 (35) 23 (0.4) 56 —
Novello et al, 2005 519 59 0 — 241 (47) 5 (1.0) 67 3 (0.6)
MacRedmond et al, 2006 449 55 0 45 111 (25) 2 (0.4) 50 4 (0.9)
I-ELCAP 2006 31567 61 17 30 4186 (13) 410 (1.3) 85 74 (0.2)
Veronesi et al, 2008 5201 58 0 44 2754 (53) 55 (1.1) 66 37 (0.7)
Overall 64475 59 20 — 12715 (20) 657 (1.0) 81 197 (0.3)
Abbreviations: CT¼computed tomography; NSM¼non-smokers; p-y¼pack-years.
aMedian age of participants.
bProportion of non-smokers.
cMedian pack-years.
dSubjects
with suspicious non-calcified solid lesions (percentage of participants).
eLung cancers detected at baseline (percentage of participants).
fPercentage of lung cancers detected in
stage I at baseline.
gLung cancers detected at first annual CT repeat.
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sampling for extensive biomarker assessment.
A pilot trial, entitled Depiscan, was launched in France in 2002,
to assess the feasibility of a screening programme with accrual
based on 232 general practitioners and occupational physicians.
The trial entered only 621 subjects in 2 years, and was closed
because of insufficient accrual (41% active investigators) and poor
compliance (Blanchon et al, 2007). At baseline, eight lung cancers
(2.4%) were detected in the CT arm and one (0.4%) in the CXR
arm. A further randomised trial is still in the planning phase in the
United Kingdom.
The DANTE study is the only European study with published
results on screening efficacy (Infante et al, 2009). After a median
follow-up of 3 years, lung cancer was detected in 60 (4.7%) subjects
receiving LDCT and in 34 (2.8%) controls (P¼0.016), with a
higher percentage of stage I lung cancer (54 vs 34%, respectively;
not significantly different: P¼0.06), corresponding to a three-fold
increase in the total number of stage I lung cancer cases (33 vs 12;
P¼0.004). However, the number of stage III–IV lung cancers was
not reduced in the LDCT arm (24 vs 21 cases), and lung cancer
mortality was identical in the two arms (20 deaths each), as well as
mortality due to other causes (26 vs 25). In summary, the mid-term
results of the first randomised trial have not confirmed LDCT
screening as having a measurable effect in diminishing lung cancer
mortality. Nonetheless, a definitive answer regarding the concrete
possibility of preventing mortality in heavy smokers with
annual LDCT screening will be determined by the long-term
follow-up of all randomised trials, the first of which is the National
Lung Screening Trial. A research priority for the coming
years will be to guarantee that all European trials, in which the
control arm is observational and intervention is prolonged beyond
3 years, can be pooled in a large meta-analysis, to reach adequate
statistical power.
ISSUES SPECIFIC TO SCREENING WITH SPIRAL CT
Prevalence of false-positive findings
The frequency of non-calcified pulmonary lesions in heavy
smokers aged X50 years is related to the sensitivity of the spiral
CT: with the 16-slice CT, the lung cancer diagnostic rate is about
1% per year, but the probability of detecting benign lesions is 50
times higher (Veronesi et al, 2008, Table 1). Consequently, the
overall screening performance depends on the selected diagnostic
algorithm.
In the Mayo CT trial, the cumulative frequency of subjects with
suspicious lesions was 74% at 5 years, but only 6% of them proved
to have cancer, with a 70% rate of false-positive findings among all
participants in the study (Swensen et al, 2005), whereas in the
Milan study, using single-slice CT and a cutoff diameter above
5mm, the frequency of subjects with suspicious lesions was only
19% at 5 years, 20% of whom proved to have cancer, with only 15%
false-positive CTs overall (Pastorino, 2006). Nonetheless, the
cumulative lung cancer detection rate was 4% in both trials
(average 0.8% per year), with other major end points such as
resectability and proportion of stage I disease being very similar.
These results are intriguing in terms of screening performance, as
one would expect a more sensitive diagnostic workup to be
associated with a better clinical outcome.
Diagnostic assessment of small pulmonary nodules requires
serial CT scanning for the detection of morphological changes, and
the availability of reliable software for fully automated three-
dimensional segmentation and highly consistent volume measure-
ment of lung nodules has become essential in evaluating growth as
evidence of potential malignancy (Wiemker et al, 2005; Marchiano `
et al, 2009).
Long-term follow-up of lesions p5mm suggests that these
nodules require no additional workup. For lesions between 5 and
10mm, surveillance of growth should be performed by three-
dimensional volumetry, as volume doubling is equivalent to only a
26% increase in diameter, a difference that may be difficult to
detect with manually guided diameter measurements. Changes in
size indicative of a doubling time ranging from 30 to 360 days are
consistent with cancer and require further investigation (Libby
et al, 2004).
Pure non-solid lesions, or ground-glass opacities, have a low
risk of malignancy (10–15%), usually represented by well-
differentiated bronchioloalveolar carcinomas (BACs), but their
volume and growth are more difficult to evaluate. Part-solid
lesions have a higher risk of malignancy (up to 50%), directly
related to the size and growth of the solid component (Henschke
et al, 2002).
Role of PET in diagnostic evaluation of positive CT screens
Large meta-analyses have demonstrated the clinical value of PET
in the differential diagnosis of undetermined pulmonary nodules
detected by spiral CT, with a sensitivity rate of 96–97%, a
specificity of 78–82%, and an accuracy rate reaching 92% with the
CT/PET fusion machine (Kim et al, 2007). Moreover, a randomised
trial demonstrated that preoperative PET significantly improves
lung cancer staging, by detecting occult metastases in otherwise
resectable patients (van Tinteren et al, 2002).
In a recent paper, we reported that selective use of PET scans
may be helpful in the management of CT-detected lesions X7mm.
In the first 5 years of screening, PET was applied to only 1.4% of
spiral CTs, with an overall sensitivity rate of 94%, specificity of
82%, and an accuracy rate of 88% (Pastorino et al, 2009). In
addition, we demonstrated that the intensity of metabolic activity,
expressed by standardised uptake value (SUV), can predict long-
term survival in screening-detected lung cancer in a non-invasive
manner. In fact, 5-year survival was 100% for SUV p2.5, 60% for
SUV 42.5 and o8, and only 20% for SUV X8( P¼0.001). If
confirmed by other studies, these results might improve the
clinical management of CT-detected tumours in the future,
reducing the risk of unnecessary treatment for indolent disease.
Table 2 Lung cancer CT screening: randomised studies
Study Country Study design Year started Subjects enrolled Age range (years) Years screen
LSS (Gohagan et al, 2005) USA CT vs CXR 2000 3318 55–74 2
DANTE (Infante et al, 2008) Italy CT vs obs 2001 2472 60–74 4
NLST (Clark et al, 2008) USA CT vs CXR 2002 53000 55–74 3
NELSON (van den Bergh et al, 2008) NL–B CT vs obs 2003 15822 50–74 5
ITALUNG (Lopes Pegna et al, 2009) Italy CT vs obs 2004 3206 55–69 5
DLCST (Pedersen et al, 2009) DK CT vs obs 2004 4104 50–70 5
MILD (Pastorino et al, 2006) Italy CT vs obs 2005 4479 49–75 10
LUSI (Becker et al, 2008) Germany CT vs obs 2007 4000 50–69 5
Abbreviation: CT¼computed tomography; CXR¼chest X-ray; DLCST¼Danish Lung Cancer Screening Trial; LSS¼Lung Screening Study; MILD¼Multicentric Italian Lung
Detection; NL–BM¼the Netherlands and Belgium; NLST¼National Lung Screening Trial; obs¼observational studies.
Lung cancer screening
U Pastorino
1683
British Journal of Cancer (2010) 102(12), 1681–1686 & 2010 Cancer Research UKOverdiagnosis of indolent tumours
Detection and treatment of slow-growing disease, also called
overdiagnosis, represents one of the most likely explanations for
the lack of mortality reduction observed in chest X-ray-screening
trials, despite a significant increase in the overall resectability rate
and proportion of stage I cancers in the intervention arm (Marcus
et al, 2006). Overdiagnosis bias refers to the screening-related
detection of cancers that would not have contributed to the death
of the patient because of competing causes of death or because the
lesion is indolent. The occurrence of slow-growing lung cancer
has often been rejected because of similar histopathological
and molecular features of screening and non-screening-detected
cases. However, the significant rise in the frequency of adeno-
carcinoma from 32% of all cases in the SEER database from 1983
to 1987 (Travis et al, 1995) to more than 70% (range 55–95%) in
CT-screening trials (Table 1 references) may well represent over-
diagnosis. An international panel has reviewed the histopatho-
logical features of 279 stage IA adenocarcinomas belonging to the
I-ELCAP database, to determine whether survival differed from
the proportion of the BAC component (Vazquez et al, 2008). The
revision confirmed that 81% of CT-detected adenocarcinomas
show a substantial BAC component, and that 5-year survival was
100% for pure BAC and 95% for mixed BAC. Such a sudden shift
towards adenocarcinoma and BAC cannot be explained by major
changes in the epidemiology of tobacco consumption, and is
strongly suggestive of an excessive detection of indolent disease by
CT screening.
Morbidity of CT screening
The side effects and morbidity of CT screening are difficult to assess
using observational studies. The frequency of surgical procedures
for benign disease, not including bronchoscopy and fine-needle
aspiration biopsy, is reported in Table 3. Invasive biopsies for
benign lesions represent, on an average, 18% (range 0–33%) of all
surgical procedures and 0.3% of individuals undergoing CT
screening. Postoperative mortality is not mentioned in most studies,
and numbers are too low for a proper estimate of the risk.
Randomised trials may allow a better evaluation of the impact of CT
screening on quality of life and proportion of unnecessary invasive
diagnostic procedures and hospital admissions, including morbidity
and mortality, by comparing the two arms.
Lung cancer mortality and survival in CT screening
In 2005, Swensen et al, comparing the lung cancer mortality rates
in the Mayo CT study with those observed in the previous CXR
trial, found no differences in lung cancer mortality rates between
the two studies in the subset of men aged 50 years or older (2.8 vs
2.0 per 1000 person-years) (Swensen et al, 2005). On the other
hand, in 2006, the International ELCAP study group published a
report on the efficacy of CT screening, in which the overall survival
of 484 screening-detected lung cancer patients was 80% at 10 years,
regardless of stage and treatment, and reached 92% in the subset of
clinical stage I resected within 1 month of diagnosis (I-ELCAP,
2006). The authors therefore concluded that CT screening could
prevent 80% of all lung cancer deaths in high-risk individuals.
However, the analysis was focused only on cancer detected at
baseline and first CT repeat, without long-term follow-up of the
entire cohort. Moreover, patients’ outcome at 10 years was
projected from a median observation period of only 3 years, and
lung cancer-specific survival was used instead of overall survival.
A concurrent meta-analysis of three single-arm studies (Mayo
Clinic, Milan and Lee Moffitt Cancer Center) including 3246
subjects and 10942 person-years was performed by the epidemio-
logists of Memorial Sloan Kettering Cancer Centre, using a
validated model to predict lung cancer incidence and mortality
(Bach et al, 2007). The results of this study, published in JAMA,
2007, demonstrated that CT screening resulted in a 3.5-fold
increase in lung cancer diagnoses and a 10-fold increase in surgical
resections. However, the number of cases of advanced lung cancer
and lung cancer death did not differ from expected numbers of
advanced lung cancer and lung cancer death, with those numbers
generated from a simulation model that used the CARET data.
Quite interestingly, the results were consistent among all three
centres, despite the potential differences in epidemiological risk
and screening methodology, mirroring the findings of the only
published randomised trial, the DANTE study, in which lung
cancer mortality was identical in the CT screening and observa-
tional arms (Infante et al, 2009). Why was earlier detection in the
first 2 years of screening not effective in preventing, at least to
some extent, the occurrence of metastatic lung cancer in the long
term? One possible explanation is that spiral CT is unable to
intercept the fast-growing or ‘most aggressive’ lung cancers before
the onset of metastases.
ROLE OF BIOMARKERS IN LUNG CANCER
SCREENING
Biomarker research in CT screening trials, combining non-invasive
genomic and proteomic analysis of target tissues, may represent a
significant improvement in early detection, offering a potential
contribution to diagnostic algorithms, assessment of individual
risk, as well as management of CT-detected cancers. The issue of
early detection biomarkers in lung cancer has recently been
reviewed by Montuenga and Pio (2009), with a focus on blood and
Table 3 Lung cancer computed tomography screening: surgical procedures for benign disease
Number of surgical procedures
Subjects Total Cancer Benign Benign disease (%)
Henschke et al, 1999 1000 28 27 1 4
Sone et al, 2001 5483 72 56 16 22
Nawa et al, 2002 7956 58 40 18 31
Sobue et al, 2002 1611 36 31 5 14
Diederich et al, 2004 817 14 11 3 21
Swensen et al, 2003 1520 83 68 15 18
Pastorino et al, 2003 1035 43 36 7 16
Bastarrika et al, 2005 911 14 14 0 0
Novello et al, 2005 519 14 12 2 14
MacRedmond et al, 2006 449 9 6 3 33
Veronesi et al, 2008 5201 107 92 15 14
Overall 26502 478 393 85 18
Lung cancer screening
U Pastorino
1684
British Journal of Cancer (2010) 102(12), 1681–1686 & 2010 Cancer Research UKsputum evaluation. Even though there is no single validated
molecular biomarker for early lung cancer detection, a complex
spectrum of molecular profiles in body fluids of subjects enrolled
in CT screening trials now offers truly innovative prospects for
early diagnosis.
For instance, proteomic analysis of plasma, using SELDI-TOF
and protein chip technology, has revealed high sensitivity and
specificity, with an 8.7-fold excess risk of cancer for CT-screened
individuals with elevated SAA protein levels (Cremona et al, 2010).
Another new field of research is represented by breathing analysis,
using electronic sensors (e-nose) to capture volatile compounds, or
to extract genomic and proteomic material from frozen exhaled
breath condensation (Horva ´th et al, 2009).
CONCLUSIONS
Prospective randomised controlled trials remain the most appro-
priate instrument to test the efficacy of CT screening in heavy
smokers. The ongoing randomised studies currently being
conducted around the world have the adequate size and
appropriate design to provide unequivocal evidence of even
modest reductions in lung cancer mortality. In the meantime, CT
screening for lung cancer should be considered as an experimental
procedure, which is not to be offered or promoted outside
controlled clinical trials. Innovative strategies could be tested to
implement early detection research, possibly combining radiolo-
gical monitoring with pharmacological intervention on smoking
cessation, and the validation of lung biomarkers.
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